MIBG and FDG PET findings in a patient with malignant pheochromocytoma: a significant discrepancy.

Abstract

Radionuclide imaging has proven to be very useful when dealing with neuroendocrine tumors and several radiotracers are currently available. One of the most commonly used and widely accepted methods to image pheochromocytomas is I-131 metaiodobenzylguanidine (MIBG) scintigraphy. However, recent studies with positron emission tomography (PET) using 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG) in pheochromocytomas have shown that FDG PET imaging can be useful in those pheochromocytomas (usually malignant) that fail to accumulate MIBG. The therapeutic plan of malignant pheochromocytoma can include chemotherapy and/or a high dose of I-131 MIBG, so precise staging and characterization is mandatory for correct management and treatment.

• Authors: Shabbir Ezuddin, Christina Fragkaki
• Journal: Clinical nuclear medicine (Clin Nucl Med) Vol. 30 Issue 8 Pg. 579-81 (Aug 2005) ISSN: 0363-9762 [Print] United States
• PMID: 16024963 (Publication Type: Case Reports, Journal Article)

Chemical References

• Radiopharmaceuticals
• Fluorodeoxyglucose F18
• 3-Iodobenzylguanidine

Topics

• 3-Iodobenzylguanidine
• Adrenal Gland Neoplasms (diagnostic imaging)
• Adult
• Fluorodeoxyglucose F18
• Follow-Up Studies
• Humans
• Male
• Neoplasm Metastasis
• Neoplasm Recurrence, Local (diagnostic imaging)
• Neoplasm Staging
• Patient Care Planning
• Pheochromocytoma (diagnostic imaging)
• Positron-Emission Tomography
• Radiopharmaceuticals